Pharmacy, Hospital Reina Sofia, Tudela, Spain
Pharmacy, Hospital Reina Sofia, Tudela, Spain.
Eur J Hosp Pharm. 2021 Jan;28(1):47-49. doi: 10.1136/ejhpharm-2018-001849. Epub 2019 May 30.
A possible case of bullous pemphigoid (BP) that developed during treatment with ustekinumab is reported. Ustekinumab is a human monoclonal antibody found in pathologies such as psoriasis, which works by inhibiting the activity of interleukin-12 and interleukin-23. We describe the case of a 75-year-old woman who presented with new onset of erythematous and bullous lesions 5 days after receiving a fifth dose of ustekinumab. The patient was treated with corticosteroids and dapsone, whereupon the lesions disappeared. Ustekinumab was withdrawn. Currently the patient remains asymptomatic. In addition, the histopathological and immunofluorescence findings confirmed the diagnosis of BP. Three causality algorithms were applied and revealed a probable causal relationship. There may be a causal relationship between the use of ustekinumab and BP. This association should be taken into account by physicians when prescribing and reviewing drug therapies.
现报告一例在乌司奴单抗治疗期间发生的大疱性类天疱疮（BP）病例。乌司奴单抗是一种在银屑病等疾病中发现的人源单克隆抗体，通过抑制白细胞介素-12 和白细胞介素-23 的活性起作用。我们描述了一例 75 岁女性的病例，她在接受第五剂乌司奴单抗后 5 天出现新发红斑和水疱性病变。患者接受了皮质类固醇和氨苯砜治疗，皮损随后消失。乌司奴单抗被停用。目前患者无症状。此外，组织病理学和免疫荧光检查结果证实了 BP 的诊断。应用了三种因果关系算法，结果显示可能存在因果关系。乌司奴单抗的使用与 BP 之间可能存在因果关系。当医生开具和审查药物治疗方案时，应考虑到这种关联。
